WERI-Rb-1Homo sapiens (Human)Cancer cell line

Also known as: Wills Eye Research Institute-Retinoblastoma-1, WERI, WERIRb1, WERI Rb-1, WERI-RB1, WERI-Rb1, WERI-Rb 1, WERI-RB-1

🤖 AI SummaryBased on 15 publications

Quick Overview

Human retinoblastoma cell line with RB1 mutation and MYCN amplification.

Detailed Summary

WERI-Rb-1 is a human retinoblastoma cell line derived from a retinal tumor. It exhibits a RB1 mutation and MYCN gene amplification, which are key genetic alterations associated with retinoblastoma progression. This cell line is commonly used in research to study the molecular mechanisms of retinoblastoma, including the role of RB1 and MYCN in tumor development and response to therapies. The cell line has been utilized in studies investigating chemoresistance, apoptosis, and the potential of targeted therapies such as NEDD8 inhibitors and MLN4924. It is also used to evaluate the efficacy of various chemotherapeutic agents and to understand the genetic and epigenetic changes that contribute to retinoblastoma malignancy.

Research Applications

RB1 mutation analysisMYCN amplification studiesChemoresistance and apoptosis researchTargeted therapy evaluation (e.g., MLN4924)Genomic and epigenetic studies

Key Characteristics

RB1 mutationMYCN amplificationUsed in drug efficacy testingRelevant for understanding retinoblastoma progression

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1792
Species	Homo sapiens (Human)
Tissue Source	Eye, globe[UBERON:UBERON_0010230]

Donor Information

Age	1
Age Category	Pediatric
Sex	Female

Disease Information

Disease	Retinoblastoma
Lineage	Eye
Subtype	Retinoblastoma
OncoTree Code	RBL

DepMap Information

Source Type	ATCC
Source ID	ACH-001421_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
Gene deletion	RB1	-	Homozygous	-	PubMed=25326674

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

D13S317

D16S539

D18S51

13,19

D19S433

14,15

D21S11

D2S1338

12,15

D3S1358

14,15

D5S818

11,12

D7S820

10,12,13

D8S1179

12,15

FGA

Penta D

12,13

Penta E

7,11

TH01

9.3

TPOX

8,11

vWA

17,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Protein profiling of WERI-RB1 and etoposide-resistant WERI-ETOR reveals new insights into topoisomerase inhibitor resistance in retinoblastoma.

Grisanti S., Joachim S.C., Mergler S., Reinhard J.

Int. J. Mol. Sci. 23:4058.1-4058.14(2022).

DOI PubMed PMC

Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy.

Aubry A., Yu T., Bremner R.

Cell Death Discov. 6:2.1-2.12(2020).

DOI PubMed PMC

Characterization of NCC-RbC-51, an RB cell line isolated from a metastatic site.

Parameswaran S., Subramaniam K.

Histochem. Cell Biol. 153:101-109(2020).

DOI PubMed

Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.

Schramm A., Temming P., Steenpass L.

Exp. Cell Res. 375:92-99(2019).

DOI PubMed

Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines.

Busch M.A., Papior D., Stephan H., Dunker N.

Oncol. Rep. 39:160-172(2018).

DOI PubMed PMC

An optimized gene transfection system in WERI-Rb1 cells.";

Liu Y., Fan Z.-G., Li K., Deng F., Xiong Y.-F., Liang M.-X., Ge J.

Int. J. Mol. Med. 40:801-813(2017).

DOI PubMed PMC

A meta-analysis of retinoblastoma copy numbers refines the list of possible driver genes involved in tumor progression.

te Riele H., Cloos J., Dorsman J.C.

PLoS ONE 11:E0153323-E0153323(2016).

DOI PubMed PMC

Re-characterization of established human retinoblastoma cell lines.";

Busch M.A., Philippeit C., Weise A., Dunker N.

Histochem. Cell Biol. 143:325-338(2015).

DOI PubMed

Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.

Boutros P.C., Lohmann D.R., Dorsman J.C., Gallie B.L.

Lancet Oncol. 14:327-334(2013).

DOI PubMed

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC

Differential CRX and OTX2 expression in human retina and retinoblastoma.

Glubrecht D.D., Kim J.-H., Russell L., Bamforth J.S., Godbout R.

J. Neurochem. 111:250-263(2009).

DOI PubMed PMC

Amplification of a DEAD box protein gene in retinoblastoma cell lines.

Godbout R., Squire J.A.

Proc. Natl. Acad. Sci. U.S.A. 90:7578-7582(1993).

DOI PubMed PMC

Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid.

Kunikane H., Tanaka Y.

J. Cancer Res. Clin. Oncol. 121:729-738(1995).

DOI PubMed

Hanganutziu-Deicher heterophile antigen in human retinoblastoma cells.

Ohashi Y., Sasabe T., Nishida T., Nishi Y., Higashi H.

Am. J. Ophthalmol. 96:321-325(1983).

DOI PubMed

Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines.

Chan H.S.L., Canton M.D., Gallie B.L.

Anticancer Res. 9:469-474(1989).

PubMed

Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression.

Chan H.S.L., Thorner P.S., Haddad G., Gallie B.L.

Ophthalmology 98:1425-1431(1991).

DOI PubMed

Characterization of a new continuous cell line derived from a human retinoblastoma.

McFall R.C., Sery T.W., Makadon M.

Cancer Res. 37:1003-1010(1977).

PubMed

Scanning electron microscopic observation of two retinoblastoma cell lines.

McFall R.C., Nagy R.M., Nagle B.T., McGreevy L.M.

Cancer Res. 38:2827-2835(1978).

PubMed

Analysis of LDH isoenzyme patterns in cell lines of the small cell carcinoma (lung) and retinoblastoma.

Higuchi H., Uei Y.

Nihon Rinsho Saibo Gakkai Zasshi 24:451-456(1985).

DOI

Web Resources

genome.ucsc.edu